- Home
- BRNS vs SCYX Comparison
BRNS vs SCYX Comparison
Compare BRNS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- SCYX
- Stock Information
- Founded
- BRNS 2016
- SCYX 1999
- Country
- BRNS United Kingdom
- SCYX United States
- Employees
- BRNS N/A
- SCYX N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- SCYX Health Care
- Exchange
- BRNS Nasdaq
- SCYX Nasdaq
- Market Cap
- BRNS 38.7M
- SCYX 40.9M
- IPO Year
- BRNS 2021
- SCYX 2014
- Fundamental
- Price
- BRNS $0.87
- SCYX $0.98
- Analyst Decision
- BRNS Strong Buy
- SCYX
- Analyst Count
- BRNS 2
- SCYX 0
- Target Price
- BRNS $3.00
- SCYX N/A
- AVG Volume (30 Days)
- BRNS 33.3K
- SCYX 71.5K
- Earning Date
- BRNS 05-07-2025
- SCYX 05-27-2025
- Dividend Yield
- BRNS N/A
- SCYX N/A
- EPS Growth
- BRNS N/A
- SCYX N/A
- EPS
- BRNS N/A
- SCYX N/A
- Revenue
- BRNS $14,969,000.00
- SCYX $3,746,000.00
- Revenue This Year
- BRNS N/A
- SCYX $460.12
- Revenue Next Year
- BRNS N/A
- SCYX $253.87
- P/E Ratio
- BRNS N/A
- SCYX N/A
- Revenue Growth
- BRNS 4381.74
- SCYX N/A
- 52 Week Low
- BRNS $0.64
- SCYX $0.73
- 52 Week High
- BRNS $2.45
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- BRNS 47.94
- SCYX 52.22
- Support Level
- BRNS $0.80
- SCYX $0.94
- Resistance Level
- BRNS $0.95
- SCYX $1.00
- Average True Range (ATR)
- BRNS 0.12
- SCYX 0.05
- MACD
- BRNS -0.00
- SCYX -0.00
- Stochastic Oscillator
- BRNS 29.70
- SCYX 37.54
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.